In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 13.76 above Generate Biomedicines Inc average.

Within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Quick Ratio than Generate Biomedicines Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 141 to 291.

Explain Quick Ratio?
How much Cash & cash equivalents GENB�s has?
What are GENB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GENB/financial-strength

https://api.csimarket.com/api/v1/companies/GENB/fundamentals

https://api.csimarket.com/api/v1/companies/GENB/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

GENB Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q2	Q1
Y / Y Current Liabilities Change	-	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	13.76	Subscribe	Subscribe	Subscribe	Subscribe
GENB's Total Ranking	# 291	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	127.81 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	50.87 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 79
Healthcare Sector	# 112
Overall Market	# 291

Quick Ratio Statistics
High	Average	Low
20.78	13.42	5.71
(Mar 31 2026)		(Dec 31 2025)

Financial Statements
Generate Biomedicines Inc 's Current Liabilities	$ 57 Millions	Visit GENB's Balance sheet
Generate Biomedicines Inc 's Cash & cash equivalent	$ 779 Millions	Visit GENB's Balance sheet
Source of GENB's Sales		Visit GENB's Sales by Geography

Cumulative Generate Biomedicines Inc 's Quick Ratio

GENB's Quick Ratio for the trailling 12 Months

GENB Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	12 Months	12 Months
Y / Y Current Liabilities TTM Growth	-	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	12.62	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	#	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	88.92 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	105.55 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to GENB Financial Strength Comparisons >> Go to Compare GENB Quick Ratio to its Competitors

On the trailing twelve months basis GENB Cash & cash equivalent soared by 50.87 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Generate Biomedicines Inc 's Quick Ratio to 12.62, Quick Ratio remained below GENB average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Quick Ratio than Generate Biomedicines Inc . While overall ranking is unchanged compared to the previous 12 months at no. 0.

Explain Quick Ratio?
How much Cash & cash equivalents GENB�s has?
What are GENB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 79
Healthcare Sector	# 112
Within the Market	# 291

trailing twelve months Quick Ratio Statistics
High	Average	Low
20.78	13.42	5.71
(Mar 31 2026)		(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Trevi Therapeutics Inc	36.50	$ 318.870 Millions	$ 8.736 Millions
Design Therapeutics Inc	35.76	$ 401.889 Millions	$ 11.240 Millions
Mineralys Therapeutics Inc	34.87	$ 673.704 Millions	$ 19.319 Millions
Praxis Precision Medicines Inc	34.32	$ 1,683.790 Millions	$ 49.058 Millions
Agios Pharmaceuticals Inc	33.94	$ 2,383.112 Millions	$ 70.217 Millions
Mbx Biosciences Inc	33.10	$ 783.099 Millions	$ 23.660 Millions
Xbiotech Inc	32.67	$ 109.528 Millions	$ 3.353 Millions
Avalo Therapeutics Inc	31.89	$ 787.143 Millions	$ 24.682 Millions
Fulcrum Therapeutics Inc	30.96	$ 318.840 Millions	$ 10.298 Millions
Climb Bio Inc	30.86	$ 183.123 Millions	$ 5.934 Millions
Indaptus Therapeutics Inc	29.61	$ 15.554 Millions	$ 0.525 Millions
Crinetics Pharmaceuticals Inc	29.41	$ 2,350.275 Millions	$ 79.915 Millions
Spyre Therapeutics Inc	28.48	$ 1,100.000 Millions	$ 38.620 Millions
Curanex Pharmaceuticals Inc	28.17	$ 2.938 Millions	$ 0.104 Millions
Onkure Therapeutics Inc	28.04	$ 186.284 Millions	$ 6.643 Millions
Ligand Pharmaceuticals Incorporated	27.33	$ 1,277.438 Millions	$ 46.736 Millions
Shattuck Labs Inc	26.94	$ 208.300 Millions	$ 7.731 Millions
Cryoport inc	26.87	$ 785.860 Millions	$ 29.244 Millions
Roivant Sciences Ltd	26.82	$ 7,607.076 Millions	$ 283.603 Millions
Neuphoria Therapeutics Inc	26.26	$ 19.866 Millions	$ 0.757 Millions
Palvella Therapeutics Inc	26.23	$ 313.381 Millions	$ 11.947 Millions
Upstream Bio Inc	26.16	$ 261.307 Millions	$ 9.988 Millions
Rallybio Corporation	26.02	$ 92.800 Millions	$ 3.567 Millions
Assembly Biosciences Inc	25.95	$ 608.475 Millions	$ 23.445 Millions
Immix Biopharma Inc	25.49	$ 238.715 Millions	$ 9.364 Millions
Boundless Bio Inc	25.00	$ 194.230 Millions	$ 7.768 Millions
Sionna Therapeutics Inc	24.88	$ 268.300 Millions	$ 10.782 Millions
Prothena Corporation Public Limited Company	24.72	$ 288.193 Millions	$ 11.658 Millions
Zenas Biopharma Inc	24.28	$ 1,597.761 Millions	$ 65.818 Millions
Innoviva Inc	23.77	$ 1,118.871 Millions	$ 47.064 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.